Enterprise value to revenue forward of Pacira Biosciences, Inc. – BX:82P
This article provides the enterprise value to forward revenue for Pacira Biosciences, Inc. (BX:82P). It is a brief financial data point from TradingView, which also lists market and company information and various tools for financial analysis. The information indicates the market was closed at the time of publication, with no trades.
If You Invested $1,000 in Pacira Biosciences Inc (PCRX)
This article analyzes the historical performance of Pacira Biosciences Inc (PCRX) stock, detailing how a $1,000 investment would have fared over 1, 5, and 10 years, and against the S&P 500. It also provides an overview of Pacira BioSciences, including its focus on non-opioid pain management, key commercial products like EXPAREL, ZILRETTA, and iovera°, its gene therapy pipeline, manufacturing operations, and financial metrics. The company aims to address prevalent conditions like osteoarthritis through innovative pain therapies.
PCRX's Exparel Wins Separate Reimbursement From UnitedHealthcare
Pacira BioSciences (PCRX) announced that UnitedHealthcare will now provide separate reimbursement for its non-opioid pain medicine, Exparel, in outpatient settings. This decision is expected to improve patient access and support the use of non-opioid pain management after surgery, following similar policies from other major insurers and expanded Medicare coverage. Exparel is Pacira's primary growth driver, with ongoing initiatives to expand its indications and geographic reach.
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®
Pacira BioSciences announced that UnitedHealthcare will now provide separate reimbursement for EXPAREL® (bupivacaine liposome injectable suspension) in outpatient settings, including hospital outpatient departments and ambulatory surgery centers. This decision expands access to non-opioid postsurgical pain management for approximately 40 million UnitedHealthcare members. With this, a total of about 150 million covered lives nationwide now have access to separate reimbursement for EXPAREL, reducing financial barriers to non-opioid pain management.
H.C. Wainwright Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $38
H.C. Wainwright has reiterated its Buy rating on Pacira BioSciences (PCRX.US) and maintained a target price of $38. This indicates the firm's continued positive outlook on the company's stock.
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL
Pacira BioSciences announced that UnitedHealthcare will now provide separate reimbursement for EXPAREL (bupivacaine liposome injectable suspension) in outpatient settings, expanding access to non-opioid postsurgical pain management for approximately 40 million covered lives. This move, following similar policies from other major payers and the NOPAIN Act, aims to remove financial barriers and support clinician-led decisions for pain management. Pacira emphasizes its commitment to collaborating with healthcare stakeholders to advance non-opioid pain therapy access and value.
Pacira BioSciences' Exparel Now Separately Reimbursed by UnitedHealthcare Across Outpatient Settings
Pacira BioSciences' Exparel, a long-acting local anesthetic, will now receive separate reimbursement from UnitedHealthcare for use in outpatient settings. This development is significant as it improves access to EXPAREL for pain management, which is a non-opioid treatment. The separate reimbursement applies to infiltration, fascial plane block, and specific nerve blocks for postsurgical pain.
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®
Pacira BioSciences announced that UnitedHealthcare will now provide separate reimbursement for EXPAREL® (bupivacaine liposome injectable suspension) across various outpatient settings. This development expands patient access to non-opioid postsurgical pain management for approximately 40 million UnitedHealthcare members. With this addition, EXPAREL now has separate reimbursement access for about 150 million covered lives nationwide, reducing financial barriers for patients seeking non-opioid pain solutions after surgery.
Price to earnings forward of Pacira BioSciences, Inc. – NASDAQ:PCRX
The article displays the "Price to earnings forward" financial metric for Pacira BioSciences, Inc. (NASDAQ: PCRX). It is presented within a TradingView interface, indicating that the data is sourced from financial services like ICE Data Services and FactSet. The page shows that market hours are closed and no trades have occurred for the stock.
Pacira Biosciences Announces Agreement To Divest Its Iovera° Business To Zimmer Biomet
Pacira Biosciences has announced an agreement to divest its Iovera° business to Zimmer Biomet. This news was reported by Reuters and Refinitiv. The article provides a brief mention of the transaction, which is less than a minute read.
Pacira BioSciences (PCRX) Sells iovera° Business to Zimmer Biome
Pacira BioSciences (PCRX) has announced the sale of its iovera° business to Zimmer Biomet for up to $140 million, including an upfront payment of $70 million. This strategic move aims to enhance Pacira's financial position and refocus resources on its core non-opioid pain management and regenerative health solutions. Despite a strong GF Score™ of 79/100, the company's high P/E ratio of 209.08x and recent insider selling of $1.0 million suggest investors should proceed with caution.
Pacira BioSciences Divests CryoTech to Zimmer Biomet
Pacira BioSciences is selling its CryoTech business, including the iovera° device, to Zimmer Biomet for up to $140 million. This deal, expected to close in Q3 2026, will help Pacira reduce debt and pivot its focus further towards biopharmaceuticals. Approximately 66 Pacira employees will transfer to Zimmer Biomet as part of the agreement.
Pacira BioSciences stock rises on Zimmer Biomet deal
Pacira BioSciences (NASDAQ:PCRX) shares rose 3.8% in premarket trading after announcing the sale of its iovera° unit to Zimmer Biomet Holdings (NYSE:ZBH) for up to $140 million. The deal includes $70 million upfront and up to $70 million in future milestone payments. Pacira intends to use the proceeds to strengthen its balance sheet and support its 5x30 strategy, transitioning into an innovative biopharmaceutical company.
Pacira offloads iovera° for up to $140M, keeps spasticity program
Pacira BioSciences announced the divestiture of its iovera° cryoneurolysis pain-treatment business to Zimmer Biomet for up to $140 million, including an upfront payment of $70 million. The companies will also collaborate on a spasticity program, with potential additional compensation for Pacira upon the successful completion of a registrational study and regulatory approval. This transaction supports Pacira's strategy to transition into an innovative biopharmaceutical company and utilize the initial proceeds to pay down its senior secured revolving credit facility.
Pacira BioSciences to Sell Iovera Cryoanalgesia Business to Zimmer for Up to $140 Million
Pacira BioSciences is divesting its iovera° cryoanalgesia business to Zimmer for a total consideration of up to $140 million. The deal includes an upfront payment of $70 million and up to $70 million in contingent payments tied to revenue milestones. This strategic move allows Pacira to refocus on core operations, with the transaction expected to finalize in the third quarter of 2026.
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet
Pacira BioSciences has announced an agreement to divest its iovera° business to Zimmer Biomet for up to $140 million, including an upfront payment of $70 million. This strategic move aligns with Pacira's 5x30 strategy and advances its transition into an innovative biopharmaceutical company, while Zimmer Biomet will gain the global rights, titles, and interests for iovera° development, manufacture, and commercialization. The companies will also collaborate on advancing a spasticity program, with Pacira potentially receiving additional compensation upon successful completion and regulatory approval.
Price to book forward of Pacira BioSciences, Inc. – NASDAQ:PCRX
This page provides financial information for Pacira BioSciences, Inc. (NASDAQ: PCRX), specifically focusing on its "Price to book forward" metric. The content highlights various financial tools and data provided by TradingView, FactSet, and ICE Data Services.
Enterprise value to EBIT forward of Pacira Biosciences, Inc. – FWB:82P
This article provides the enterprise value to EBIT forward for Pacira Biosciences, Inc. (FWB:82P) on the Frankfurt Stock Exchange. It indicates that the market was closed with no trades at the time of the report. The content also briefly outlines the navigation sections available on the TradingView platform for this stock.
Price to earnings forward of Pacira Biosciences, Inc. – FWB:82P
This page displays the "Price to earnings forward" metric for Pacira Biosciences, Inc. (FWB:82P) on the Frankfurt Stock Exchange. The current value for this financial indicator is presented, along with the option to view change and change percentage over a period.
Pacira Biosciences, Inc. Actuals & Estimates (NASDAQ:PCRX)
This article provides comprehensive financial data and analyst estimates for Pacira BioSciences, Inc. (PCRX), covering its stock performance, future price forecasts, and key financial metrics. It details current stock price, market capitalization, historical highs and lows, and upcoming earnings report dates, noting that the company does not pay dividends.
Pacira Biosciences, Inc. Actuals & Estimates (FWB:82P)
This article provides financial actuals and estimates for Pacira Biosciences, Inc. (FWB:82P), including income statement, balance sheet, and cash flow data. It also details analyst price targets, historical stock prices, upcoming earnings reports, and key financial metrics like revenue, net income, EBITDA, and employee count.
Pacira Biosciences, Inc. Actuals & Estimates (SWB:82P)
This article provides an overview of Pacira Biosciences, Inc. (SWB:82P) financial actuals and analyst estimates, including income statement, balance sheet, and cash flow data. It details the company's past earnings, revenue, and net income, alongside future earnings and revenue expectations. Additionally, it addresses various frequently asked questions about the stock, such as its ticker, forecast, historical prices, and dividend policy.
Pacira Biosciences Inc (PCRX) Financial Health: Profitability & Balance Sheet Analysis
Pacira Biosciences Inc (PCRX) currently has a strong financial score of 8.79, ranking 34 out of 157 in the Pharmaceuticals industry, indicating stable financial status and high operating efficiency. The company reported a significant year-over-year revenue increase of 5.00% and a net profit increase of 39.40% in its latest quarter. Key financial metrics such as Quality of Earnings, Operational Efficiency, and Growth Potential all received high scores, suggesting robust performance.
Pacira Biosciences Inc (PCRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Pacira Biosciences Inc (PCRX), detailing its price momentum, support and resistance levels, and signals from various technical indicators and moving averages. The stock currently has a price momentum score of 6.55 and is trading between a resistance of $24.57 and support of $21.32. Based on the indicators and moving averages, the overall signal for PCRX is "Sell."
Pacira Biosciences Inc (PCRX) Institutional Confidence
Pacira Biosciences Inc (PCRX) has an institutional shareholding score of 10.00, placing it first in the Pharmaceuticals industry. The institutional shareholding proportion is 122.53%, showing a 1.68% quarter-over-quarter increase. The largest holder is James Simons, with 4.64% of outstanding shares.
Pacira Biosciences Inc (PCRX) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Pacira Biosciences Inc (PCRX), detailing its current earnings forecast score, average price target, and analyst ratings. Based on 6 analysts, most support a "Buy" trend with a target price of $29.67 and an expected upside of 30.46%. The company's expected revenue for the next quarter is $190.82 million, and the EPS is projected at $0.65.
Precision Trading with Pacira Biosciences Inc. (PCRX) Risk Zones
This article from Stock Traders Daily discusses precision trading strategies for Pacira Biosciences Inc. (PCRX), highlighting a weak near-term sentiment that could lead to bearish positioning. It outlines specific long, breakout, and short trading strategies with entry and target prices, stop-loss levels, and risk-reward ratios. The analysis is supported by AI-generated signals and multi-timeframe signal analysis for various holding periods.
Precision Trading with Pacira Biosciences Inc. (PCRX) Risk Zones
This article analyzes Pacira Biosciences Inc. (PCRX), highlighting a weak near-term sentiment that could lead to bearish positioning. It details a high risk-reward short setup with a significant downside target, and provides three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis.
Pacira BioSciences SVP Lauren Riker sells $143,702 in stock
Lauren Riker, SVP of Finance at Pacira BioSciences (NASDAQ:PCRX), sold 6,115 shares of company stock for $143,702. The sale, executed under a Rule 10b5-1 trading plan, leaves Riker with over 62,000 shares. Despite the insider sale, InvestingPro analysis suggests the stock is undervalued, and the company has been aggressively buying back shares and maintains a strong Piotroski Score.
Pacira (PCRX) director receives RSU and stock option grants
Pacira BioSciences director Christopher Christie received 6,405 restricted stock units and a stock option for 10,891 shares, both vesting on June 10, 2027, provided he maintains continuous service. The stock option has an exercise price of $23.42 per share and expires on June 10, 2036. Following these non-open-market, compensation-related grants, Christie directly holds 23,059 shares of Pacira common stock.
Insider Sell: Lauren Riker Sells Shares of Pacira BioSciences In
Lauren Riker, Senior Vice President of Finance at Pacira BioSciences Inc., sold 6,115 shares of the company on June 11, 2026, reducing her holdings to 62,284.242 shares. This transaction follows a pattern of 14 insider sells and no insider buys at Pacira BioSciences Inc. over the past year. Despite a high P/E ratio, the stock is considered modestly undervalued based on its GuruFocus Value.
Pacira BioSciences (PCRX) director receives new RSUs and stock options
Pacira BioSciences director Samit Hirawat was granted 6,405 restricted stock units (RSUs) and stock options for 10,891 shares. Both awards vest on June 10, 2027, provided he remains in continuous service with the company. The stock options have an exercise price of $23.42 per share and expire on June 10, 2036.
Pacira BioSciences (PCRX) director receives RSU and stock option grants
Pacira BioSciences director Alethia Young received equity compensation including 6,405 restricted stock units and 10,891 stock options on June 10, 2026. Both the RSUs and options vest on June 10, 2027, contingent on her continuous service with the company. Following these grants, Young directly holds 17,798 shares of common stock, in addition to the newly granted options.
Pacira BioSciences SVP Lauren Riker sells $143,702 in stock
Lauren Riker, SVP of Finance at Pacira BioSciences, sold $143,702 worth of company stock on June 11, 2026, as part of a Rule 10b5-1 trading plan. Despite the stock being down, InvestingPro Tips indicate aggressive share buybacks and strong financial health for Pacira BioSciences. The company recently reported robust Q1 2026 financial results, with increased revenue for its key products EXPAREL, ZILRETTA, and iovera.
Pacira BioSciences (NASDAQ: PCRX) director Thomas Wiggans files Form 3
Pacira BioSciences director Thomas G. Wiggans has filed a Form 3, an initial statement of beneficial ownership for insiders. The filing indicates no reported transactions, with zero shares bought, sold, acquired, or disposed. This Form 3 establishes a baseline for Wiggans' beneficial ownership without any current trading activity.
Pacira BioSciences (PCRX) director granted 32,675 stock options at $23.42
Pacira BioSciences (PCRX) director Thomas G. Wiggans received a grant of 32,675 stock options with an exercise price of $23.42 per share, expiring on June 10, 2036. The options will vest over three years, with one-third vesting after the first year and the remainder in equal monthly installments over the subsequent two years, contingent on his continued service. This transaction is classified as a compensation-related grant rather than a market purchase or sale.
Pacira BioSciences (PCRX) director Laura Brege receives stock and option awards
Laura Brege, a director at Pacira BioSciences (PCRX), was granted 6,405 restricted stock units and options for 10,891 shares at an exercise price of $23.42. These equity awards, reported in a Form 4 SEC filing, will vest on June 10, 2027, contingent upon her continuous service with the company. Following these transactions, Brege directly holds 30,120 shares of Pacira common stock.
Pacira BioSciences (NASDAQ: PCRX) SVP Finance sells shares under 10b5-1 plan
Pacira BioSciences' Senior Vice President of Finance, Lauren Riker, sold 6,115 shares of common stock at $23.50 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026. Following the sale, Riker directly holds 62,284.242 shares in the company.
Pacira BioSciences (PCRX) director receives new RSU and stock option awards
Pacira BioSciences director Michael J. Yang received new equity awards on June 10, 2026, consisting of 6,405 restricted stock units and a stock option for 10,891 shares at an exercise price of $23.42 per share. Both awards vest or become exercisable on June 10, 2027, contingent on his continuous service. Following these grants, Yang directly holds 19,798 shares of common stock, which is considered routine compensation aimed at aligning his long-term incentives with the company's performance.
PCRX (NASDAQ) shows 2,876 and 6,163 restricted shares vesting
Pacira BioSciences, Inc. (PCRX) has filed a Form 144 notice indicating upcoming restricted stock vesting. The filing details 2,876 shares set to vest on June 12, 2025, and another 6,163 shares vesting on June 9, 2026. Fidelity Brokerage Services LLC is named as the broker in these compensation-related transactions.
Pacira BioSciences (NASDAQ:PCRX) Stock Crosses Below 50 Day Moving Average - Should You Sell?
Pacira BioSciences (NASDAQ:PCRX) stock recently dropped below its 50-day moving average, trading at $23.36 after a 0.3% decline. Despite a "Hold" consensus rating and an average target price of $29.40, the company missed EPS expectations in its latest earnings report, though revenue increased. Insider sales, including by CFO Shawn Cross, have also been noted.
Pacira (NASDAQ: PCRX) investors reelect board nominees and add 800,000 ESPP shares
Pacira BioSciences, Inc. shareholders reelected all three company-nominated Class III directors, Christopher J. Christie, Samit Hirawat, and Thomas Wiggans, over an opposing slate from DOMA Perpetual Capital Management LLC. Stockholders also approved an amendment to the 2014 Employee Stock Purchase Plan, adding 800,000 shares, and ratified KPMG LLP as the independent auditor. However, an amendment to the 2011 Stock Incentive Plan did not receive enough votes for approval.
[144] Pacira BioSciences, Inc. SEC Filing
This article reports on a Form 144 SEC filing by Pacira BioSciences, Inc. (PCRX) on June 11, 2026. The filing indicates a neutral impact and sentiment, detailing a proposed sale of 6,115 shares of common stock with an aggregate market value of $143,702.50 by an unnamed individual, acquired through restricted stock vesting. The report also includes recent news and SEC filings related to Pacira BioSciences.
Biotech company shareholders elect Chris Christie in rejecting activist investor's slate
Shareholders of Pacira Biosciences have elected former New Jersey Governor Chris Christie to their board, rejecting a slate of directors proposed by an activist investor. This decision marks a victory for Christie in a corporate dispute within a Bay Area company.
Shareholders elect Pacira's three board picks in preliminary vote
Pacira BioSciences announced that based on preliminary results from its 2026 Annual Meeting of Stockholders, all three company director nominees — Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans — were elected to the board. The company's CEO, Frank D. Lee, expressed gratitude to stockholders and affirmed the commitment to executing their "5x30 strategy" to drive long-term value. Final results will be certified and filed on Form 8-K with the SEC.
Pacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting
Pacira BioSciences announced that its stockholders have elected all three of the company's director nominees – Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans – to the Board of Directors at its 2026 Annual Meeting. CEO Frank D. Lee expressed gratitude to stockholders and affirmed the company's commitment to its 5x30 strategy for long-term value creation. The preliminary results will be formally certified and reported in a Form 8-K filing.
Pacira (PCRX) CAO sells 10,259 shares under pre-set 10b5-1 trading plan
Pacira BioSciences' Chief Administrative Officer, Kristen Williams, sold 10,259 shares of common stock for $22.27 per share on June 4, 2026, under a pre-arranged 10b5-1 trading plan. This transaction, totaling approximately $228,468, follows a separate disposition of 8,528 shares on June 3, 2026, which were withheld to cover tax obligations from a restricted stock unit award. After these transactions, Williams directly holds 167,062 Pacira shares.
Pacira BioSciences (NASDAQ: PCRX) CMO has 4,728 shares withheld for taxes
Pacira BioSciences' Chief Medical Officer, Jonathan Slonin, reported a routine tax-related share disposition where 4,728 shares of common stock were withheld to cover tax obligations upon the vesting of a restricted stock unit award. This was not an open-market sale or purchase. After this transaction, Slonin directly holds 218,912.175 shares of Pacira BioSciences common stock.
Pacira (PCRX) SVP has 3,187 shares withheld for tax obligations
Pacira BioSciences' Senior Vice President of Finance, Lauren Riker, had 3,187 shares of common stock withheld by the company at $22.32 per share to cover tax obligations upon the vesting of a restricted stock unit award. This was a routine, compensation-related event rather than an open-market sale. Following this transaction, Riker directly holds 68,399.242 shares of Pacira common stock.
Pacira BioSciences CAO Kristen Williams sells $228,467 in stock
Kristen Williams, Chief Administrative Officer of Pacira BioSciences, recently sold shares totaling $228,467. These transactions included a sale executed via a Rule 10b5-1 trading plan and shares withheld for tax obligations from a restricted stock unit award. Following these sales, Ms. Williams directly holds 167,062 shares of the company's common stock.
